Cash flow conversion remains highly volatile, evidenced by an OCF/NI ratio that swung from a negative 0.95 in 2023Q4 to 110.80 in 2025Q4, complicating the assessment of sustainable free cash flow generation.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 23.15B | 19.7B | 24.2B | 29.07B | 26.21B | 22.34B | 22.17B | 18.46B | 15.71B | 13.6B | 9.79B | 9.74B | 8.05B | 6.99B | 7.16B | 6.97B | 6.27B | 5.63B | 4.24B | 5.88B | 6.53B | 4.33B | 4.13B | 3B | 2.42B | 1.84B | 1.52B | 1.19B | 1.07B | 683M | 562.26M |
| Operating CF Growth % | -40.7% | -18.62% | -16.73% | 10.92% | 17.29% | 0.76% | 20.1% | 17.5% | 15.57% | 38.81% | 0.56% | 20.98% | 15.16% | -2.29% | 2.68% | 11.08% | 11.52% | 32.73% | -27.89% | -9.94% | 50.86% | 4.62% | 37.7% | 23.94% | 31.4% | 21.24% | 27.92% | 11.02% | 56.81% | 21.47% | 29.47% |
| Operating CF / Revenue % | 5.15% | 4.4% | 6.05% | 7.82% | 8.08% | 7.77% | 8.62% | 7.62% | 6.95% | 6.76% | 5.3% | 6.2% | 6.17% | 5.71% | 6.47% | 6.84% | 6.66% | 6.46% | 5.22% | 7.79% | 9.12% | 9.32% | 11.11% | 10.51% | 9.68% | 7.86% | 7.2% | 6.08% | 6.17% | 5.79% | 5.58% |
| Net Income | 12.04B | 12.81B | 15.24B | 22.38B | 20.12B | 17.29B | 15.77B | 13.84B | 11.99B | 10.56B | 7.02B | 5.81B | 5.62B | 5.63B | 5.53B | 5.14B | 4.63B | 3.82B | 2.98B | 4.65B | 4.16B | 3.3B | 2.59B | 1.82B | 1.35B | 913M | 736M | 568M | -166M | 460M | 355.64M |
| Depreciation & Amortization | 4.33B | 4.36B | 4.1B | 3.97B | 3.4B | 3.1B | 2.89B | 2.72B | 2.43B | 2.25B | 2.06B | 1.69B | 1.48B | 1.38B | 1.31B | 1.12B | 1.06B | 991M | 981M | 796M | 670M | 453M | 374M | 299M | 255M | 265M | 247M | 233M | 185M | 146M | 133.17M |
| Stock-Based Compensation | 944M | 971M | 1.02B | 1.06B | 925M | 800M | 679M | 697M | 638M | 597M | 485M | 406M | 364M | 331M | 421M | 401M | 326M | 334M | 305M | 505M | 404M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -817M | -989M | -296M | -245M | -673M | -814M | -60M | 230M | 42M | -748M | 81M | -308M | -415M | 1M | 5M | -8M | 248M | 7M | -166M | -127M | -267M | 167M | 125M | 91M | 154M | 40M | 73M | 35M | -184M | 91M | 0 |
| Other Non-Cash Items | 225M | 265M | 4.95B | 258M | 188M | 447M | 0 | 294M | 325M | 265M | -26M | 55M | 0 | -35M | 0 | 0 | 0 | 0 | -122M | 0 | 0 | 0 | 0 | 0 | -506M | -287M | -465M | -353M | -98M | 14M | 704K |
| Working Capital Changes | 5.66B | 2.28B | -808M | 1.64B | 2.25B | 1.52B | 2.9B | 683M | 294M | 679M | 183M | 2.08B | 1B | -306M | -106M | 309M | 1M | 471M | 263M | 49M | 1.56B | 406M | 1.05B | 788M | 1.17B | 913M | 930M | 706M | 1.33B | -28M | 72.75M |
| Cash from Investing | -10.89B | -8.69B | -20.53B | -15.57B | -28.48B | -10.37B | -12.53B | -12.7B | -12.38B | -8.6B | -9.36B | -18.39B | -2.53B | -3.09B | -8.65B | -4.17B | -5.34B | -976M | -5.07B | -4.15B | -2.1B | -3.49B | -1.64B | -745M | -1.39B | -1.14B | -968M | -623M | 21M | -1B | -472.51M |
| Capital Expenditures | -3.49B | -3.62B | -3.5B | -3.39B | -2.8B | -2.45B | -2.05B | -2.07B | -2.06B | -2.02B | -1.71B | -1.56B | -1.45B | -1.16B | -1.07B | -1.07B | -878M | -739M | -791M | -871M | -728M | -509M | -350M | -352M | -419M | -425M | -245M | -196M | -210M | -187M | -165.22M |
| Acquisitions | -3.81B | -4.51B | -13.41B | -10.14B | -21.46B | -4.82B | -7.14B | -8.34B | -6B | -2.13B | -1.76B | -16.16B | -1.92B | -317M | -6.28B | -1.41B | -2.3B | -486M | -3.81B | -262M | -670M | -2.92B | -2.23B | -590M | -302M | -92M | -76M | -334M | -464M | 0 | -51.86M |
| Purchase of Investments | 1.78B | 0 | -27.31B | -18.31B | -18.82B | -1.84B | -16.58B | -2.5B | -4.1B | -4.32B | -5.93B | -531M | -9.93B | -1.61B | -1.3B | -9.89B | -2.16B | -6.47B | -9.25B | -6.38B | -4.85B | -5.88B | -3.19B | -2.58B | -3.25B | -2.09B | -3.02B | -2.21B | -2.8B | -6.71B | -5.01B |
| Sale/Maturity of Investments | -4.99B | 361M | 27.83B | 16.54B | 11.99B | 15.3B | 13.74B | 15.63B | 9.91B | 10.27B | 11.62B | 9.41B | 799M | 10.56B | 8.6B | 8.2B | 5.7B | 249M | 8.6B | 3.37B | 4.1B | 5.82B | 4.12B | 2.78B | 2.58B | 1.47B | 2.36B | 2.06B | 3.44B | 5.89B | 4.75B |
| Other Investing | -386M | -915M | -4.14B | -275M | 2.62B | -16.55B | -506M | -15.41B | -10.14B | -10.39B | -11.58B | -9.55B | 9.96B | -10.56B | -8.6B | 0 | -5.7B | 6.47B | 185M | 0 | 52M | 0 | 0 | 0 | 0 | 0 | 12M | 51M | 59M | 0 | -1.5M |
| Cash from Financing | -14.73B | -11.64B | -3.51B | -11.53B | 4.23B | -7.46B | -3.59B | -5.63B | -4.37B | -3.44B | -1.01B | 12.24B | -5.29B | -4.95B | 471M | -2.49B | -1.61B | -2.27B | -605M | -3.19B | 474M | 593M | -762M | -1.13B | -1.44B | -585M | -739M | -605M | -198M | 34M | 6.86M |
| Dividends Paid | -8.01B | -7.92B | -7.53B | -6.76B | -5.99B | -5.28B | -4.58B | -3.93B | -3.32B | -2.77B | -2.26B | -1.79B | -1.36B | -1.06B | -820M | -651M | -449M | -36M | -37M | -40M | -41M | -19M | -18M | -9M | -9M | -9M | -5M | -6M | -34M | -35M | -34.09M |
| Share Repurchases | -2.54B | -5.54B | -9B | -8B | -7B | -5B | -4.25B | -5.5B | -4.5B | -1.5B | -1.28B | -1.2B | -4.01B | -3.17B | -3.08B | -2.99B | -2.52B | -1.8B | -2.68B | -6.6B | -2.35B | -2.56B | -3.45B | -1.61B | -1.81B | -1.13B | -1.18B | -983M | -436M | -16M | 0 |
| Stock Issued | -360M | 0 | 1.85B | 1.35B | 1.25B | 1.35B | 1.44B | 1.04B | 838M | 688M | 429M | 402M | 462M | 598M | 1.08B | 381M | 272M | 282M | 299M | 712M | 397M | 423M | 583M | 268M | 205M | 178M | 228M | 102M | 84M | 79M | 41.56M |
| Debt Issuance (Net) | -2M | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | -620K |
| Other Financing | -236M | 1.09B | -3.48B | -2.4B | 3.43B | 344M | 2.66B | -187M | -679M | 3.45B | 1.54B | 618M | -314M | -872M | -1.27B | 428M | 989M | 729M | 682M | -827M | 1.89B | 90M | 75M | 4M | 0 | 0 | 0 | 0 | 0 | 6M | 0 |
| Net Change in Cash | 1.07B | 2.81B | -115M | 2.06B | 1.99B | 4.45B | 5.94B | 119M | -1.11B | 1.55B | -493M | 3.43B | 219M | -1.13B | -1.02B | 306M | -677M | 2.37B | -1.44B | -1.46B | 4.9B | 1.43B | 1.73B | 1.13B | -410M | 121M | -186M | -39M | 894M | -287M | 96.61M |
| Exchange Rate Effect | 3.54B | 3.44B | -280M | 97M | 34M | -62M | -116M | -20M | -78M | -5M | 78M | -156M | -5M | -86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 24.36B | 25.31B | 25.43B | 23.36B | 21.38B | 16.92B | 10.98B | 10.87B | 11.98B | 10.43B | 10.92B | 7.5B | 7.28B | 8.41B | 9.43B | 9.12B | 9.8B | 7.43B | 8.87B | 10.32B | 5.42B | 3.99B | 2.26B | 1.13B | 1.54B | 1.42B | 1.6B | 1.64B | 750M | 1.04B | 940.11M |
| Cash at End | 28B | 28.12B | 25.31B | 25.43B | 23.36B | 21.38B | 16.92B | 10.98B | 10.87B | 11.98B | 10.43B | 10.92B | 7.5B | 7.28B | 8.41B | 9.43B | 9.12B | 9.8B | 7.43B | 8.87B | 10.32B | 5.42B | 3.99B | 2.26B | 1.13B | 1.54B | 1.42B | 1.6B | 1.64B | 750M | 1.04B |
| Free Cash Flow | 19.67B | 16.07B | 20.7B | 25.68B | 23.4B | 19.89B | 20.12B | 16.39B | 13.65B | 11.57B | 8.09B | 8.18B | 6.6B | 5.83B | 6.08B | 5.95B | 5.39B | 4.89B | 3.45B | 5.01B | 5.8B | 3.82B | 3.79B | 2.65B | 2B | 1.42B | 1.28B | 993M | 861M | 496M | 397.04M |
| FCF Growth % | -20.9% | -22.36% | -19.38% | 9.73% | 17.67% | -1.16% | 22.76% | 20.09% | 17.95% | 43.05% | -1.15% | 23.92% | 13.28% | -4.19% | 2.27% | 10.29% | 10.42% | 41.75% | -31.14% | -13.66% | 51.9% | 0.85% | 42.78% | 32.29% | 41.23% | 11.21% | 28.5% | 15.33% | 73.59% | 24.93% | 22.15% |
| FCF Margin % | 4.37% | 3.59% | 5.17% | 6.91% | 7.22% | 6.92% | 7.83% | 6.77% | 6.03% | 5.75% | 4.38% | 5.21% | 5.06% | 4.76% | 5.5% | 5.84% | 5.73% | 5.61% | 4.25% | 6.64% | 8.1% | 8.22% | 10.17% | 9.28% | 8.01% | 6.05% | 6.04% | 5.08% | 4.96% | 4.21% | 3.94% |
| FCF per Share | 21.61 | 17.66 | 22.29 | 27.38 | 24.64 | 20.8 | 20.94 | 16.97 | 13.89 | 11.75 | 8.36 | 8.46 | 6.7 | 5.7 | 5.82 | 5.47 | 4.77 | 4.14 | 2.78 | 3.68 | 4.14 | 2.86 | 2.88 | 2.15 | 1.58 | 1.09 | 0.95 | 0.7 | 0.56 | 0.32 | 0.27 |
Medical utilization cost inflation
According to quarterly financial disclosures, the OCF/NI ratio has exhibited extreme volatility, ranging from a negative 0.95 in 2023Q4 to a peak of 110.80 in 2025Q4, indicating that reported net income is a poor proxy for the company's actual cash-generating capacity during periods of operational disruption.
The significant disconnect between net income and operating cash flow suggests that non-cash charges and working capital swings are heavily distorting the bottom line. Investors should monitor whether this divergence reflects genuine accounting noise or an underlying inability to convert service-based earnings into realized cash inflows.
As reported in recent financial statements, FCF margins have fluctuated wildly from a negative 6.5% in 2023Q4 to a high of 12.8% in 2024Q3, reflecting a highly inconsistent ability to translate top-line revenue into sustainable free cash flow amidst ongoing medical cost pressures.
The erratic FCF trajectory implies that the company's cash generation is highly sensitive to the timing of medical claims payments and regulatory reimbursement cycles. This instability warrants further investigation into whether the current cost structure can support consistent dividend and buyback programs without relying on debt financing.
Based on the provided cash flow data, working capital changes have swung from a massive $11.9 billion outflow in 2023Q4 to a $7.3 billion inflow in 2024Q3, highlighting the extreme sensitivity of the company's liquidity position to fluctuations in claims processing and accounts payable management.
These dramatic shifts in working capital appear to be the primary driver of the company's inconsistent cash flow performance. The reliance on large swings in payables to manage liquidity suggests that the firm may be using its scale to defer obligations, which could create future cash flow bottlenecks.
As evidenced by recent SEC filings, the company has maintained aggressive capital deployment through dividends and share repurchases, even as FCF margins have compressed, with buybacks totaling $4.7 billion in 2025Q3 despite significant volatility in the underlying cash-generating capacity of the core insurance business.
The commitment to returning capital to shareholders during periods of operational strain suggests a management focus on supporting the stock price, which may come at the expense of necessary reinvestment in the Optum service infrastructure. Investors should monitor whether this allocation strategy remains sustainable if medical utilization trends continue to pressure margins.
Quick answers to the most common questions about buying UNH stock.
UnitedHealth Group Incorporated (UNH) generated $19.70B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
UnitedHealth Group Incorporated (UNH) generated $16.07B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
UnitedHealth Group Incorporated (UNH) spent $3.62B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, UnitedHealth Group Incorporated (UNH) returned $7.92B to shareholders via cash dividends and spent $5.54B on share repurchases. This shows the company's commitment to returning capital to its equity investors.